Acutaas Chemicals

Acutaas Chemicals delivered a stellar Q4 FY26 with revenue of 432.8 crCurrent reported value: 432.8 cr. No comparable prior figure is available in the source record. (+40.3Current reported value: 40.3. No comparable prior figure is available in the source record.% YoY) and EBITDA of 183.5 crCurrent reported value: 183.5 cr. No comparable prior figure is available in the source record. (margin 42.4%Current reported value: 42.4%. No comparable prior figure is available in the source record., +1487 bps YoY), driven by strong CDMO ramp-up, portfolio reshuffling, and operating leverage. PAT more than doubled to 134.3 crCurrent reported value: 134.3 cr. No comparable prior figure is available in the source record.. Management guided for 25% revenue growthCurrent reported value: 25% revenue growth. No comparable prior figure is available in the source record. in FY27 and stable EBITDA margins, supported by battery electrolyte additive commercialization, four new CDMO products in validation, and recovery in semiconductor chemicals (BFC). The South Korea JV (Indicam) is on track for H2 CY26 commissioning. Key risk: global supply chain disruptions from Gulf conflict could pressure raw material costs and margins.